Effect of Bisoprolol on the Level of Dabigatran.
Adrenergic beta-Antagonists
/ adverse effects
Aged
Aged, 80 and over
Anti-Arrhythmia Agents
/ pharmacokinetics
Atrial Fibrillation
/ drug therapy
Bisoprolol
/ adverse effects
Cardiotonic Agents
/ adverse effects
Dabigatran
/ pharmacokinetics
Digoxin
/ adverse effects
Drug Interactions
Female
Humans
Male
Middle Aged
Pilot Projects
Proton Pump Inhibitors
/ adverse effects
Journal
American journal of therapeutics
ISSN: 1536-3686
Titre abrégé: Am J Ther
Pays: United States
ID NLM: 9441347
Informations de publication
Date de publication:
Historique:
pubmed:
4
8
2018
medline:
24
11
2020
entrez:
4
8
2018
Statut:
ppublish
Résumé
Many patients receiving dabigatran treatment might also require bisoprolol therapy. However, there is a possibility that bisoprolol as significant P-glycoprotein inhibitor might interact with dabigatran. To investigate the impact of concomitant bisoprolol therapy on dabigatran plasma level in patients with nonvalvular atrial fibrillation. A pilot drug interaction study in 29 patients with nonvalvular atrial fibrillation on dabigatran therapy. Bisoprolol was administrated in 18 patients. Blood samples were collected at baseline (in the morning, before any medication was administered) and at hour 2 (2 hours after administration of dabigatran and bisoprolol). The dabigatran plasma level was significantly higher at baseline and at hour 2 in patients treated with bisoprolol compared with patients without bisoprolol therapy. In addition, we have shown that this increase is affected by dabigatran dosage and concomitant treatment with proton-pump inhibitor and digoxin. The impact of bisoprolol on dabigatran concentration was still significant despite these confounders. This study demonstrated the interaction between dabigatran and bisoprolol, which is modulated with dabigatran dosage and concomitant treatment with proton-pump inhibitor and digoxin.
Sections du résumé
BACKGROUND
BACKGROUND
Many patients receiving dabigatran treatment might also require bisoprolol therapy. However, there is a possibility that bisoprolol as significant P-glycoprotein inhibitor might interact with dabigatran.
STUDY QUESTION
OBJECTIVE
To investigate the impact of concomitant bisoprolol therapy on dabigatran plasma level in patients with nonvalvular atrial fibrillation.
STUDY DESIGN
METHODS
A pilot drug interaction study in 29 patients with nonvalvular atrial fibrillation on dabigatran therapy. Bisoprolol was administrated in 18 patients. Blood samples were collected at baseline (in the morning, before any medication was administered) and at hour 2 (2 hours after administration of dabigatran and bisoprolol).
RESULTS
RESULTS
The dabigatran plasma level was significantly higher at baseline and at hour 2 in patients treated with bisoprolol compared with patients without bisoprolol therapy. In addition, we have shown that this increase is affected by dabigatran dosage and concomitant treatment with proton-pump inhibitor and digoxin. The impact of bisoprolol on dabigatran concentration was still significant despite these confounders.
CONCLUSIONS
CONCLUSIONS
This study demonstrated the interaction between dabigatran and bisoprolol, which is modulated with dabigatran dosage and concomitant treatment with proton-pump inhibitor and digoxin.
Identifiants
pubmed: 30074534
doi: 10.1097/MJT.0000000000000786
pii: 00045391-202003000-00004
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Anti-Arrhythmia Agents
0
Cardiotonic Agents
0
Proton Pump Inhibitors
0
Digoxin
73K4184T59
Dabigatran
I0VM4M70GC
Bisoprolol
Y41JS2NL6U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e159-e164Références
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
Kotecha D, Calvert M, Deeks JJ, et al. A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. BMJ Open. 2017;7:e015099.
Gooden JY, Powell BD, Akogyeram CO, et al. Recent advances in the pharmacological management of atrial fibrillation. Am J Ther. 2016;23:e118–e138.
Sunbul M, Cincin A, Mammadov C, et al. Is dabigatran as effective as warfarin on cardiac thrombus in a patient with atrial Fibrillation? A challenging question. Am J Ther. 2016;23:e974–e976.
Kannan A, Poongkunran C, Shenoy S, et al. Perioperative management of anticoagulation-review of latest evidence. Am J Ther. 2016;23:e474–e484.
Wessler JD, Grip LT, Mendell J, et al. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013;61:2495–2502.
Weiss RJ, Rauscher A, Shaw D. Effect of bisoprolol and atenolol on left ventricular mass in patients with essential hypertension. Am J Ther. 1994;1:81–85.
Kakumoto M, Sakaeda T, Takara K, et al. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci. 2003;94:81–86.
Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–236.
Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology. 2015;149:586–595.
Ollier E, Hodin S, Basset T, et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol. 2015;29:604–614.